Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?

The act of nonmedical switching, defined as switching stable patients who are generally doing well with their current therapy from an originator biologic to its biosimilar, has been endorsed as a reasonable treatment strategy. The safety and efficacy of nonmedical switching have been evaluated in ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Roy, Jairath, Vipul, Mysler, Eduardo, Nicholls, Dave, Declerck, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021884/
https://www.ncbi.nlm.nih.gov/pubmed/31950442
http://dx.doi.org/10.1007/s40744-019-00190-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021884/
https://www.ncbi.nlm.nih.gov/pubmed/31950442
http://dx.doi.org/10.1007/s40744-019-00190-7

Ejemplares similares